NCT07591506

Brief Summary

This prospective randomized clinical study evaluates the role of intraoperative frozen section examination of sentinel lymph nodes in patients with breast cancer. The study aims to determine whether frozen section assessment during surgery improves intraoperative decision-making and affects surgical management when compared with standard final pathological evaluation performed after surgery.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
142

participants targeted

Target at P50-P75 for not_applicable

Timeline
11mo left

Started May 2026

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress6%
May 2026May 2027

Study Start

First participant enrolled

May 1, 2026

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

May 3, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

May 15, 2026

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

May 15, 2026

Status Verified

May 1, 2026

Enrollment Period

1 year

First QC Date

May 3, 2026

Last Update Submit

May 11, 2026

Conditions

Keywords

sentinel lymph node biopsyfrozen sectionbreast cancerintraoperative pathologyaxillary staging

Outcome Measures

Primary Outcomes (1)

  • Number of participants randomized to the frozen section group and the routine histopathology group

    Count of participants randomized by sealed-envelope method to either intraoperative frozen section evaluation of sentinel lymph nodes or routine histopathological evaluation after formalin fixation. This outcome will be reported as the total number of randomized participants until the protocol-defined target sample size for between-group comparison is reached (planned total sample size: 142 participants).

    From first participant enrollment until the target sample size is reached, up to 1 year

Secondary Outcomes (1)

  • Percentage of participants in the routine histopathology group who require axillary lymph node dissection

    From surgery until final histopathological evaluation and multidisciplinary treatment decision, up to 30 days

Study Arms (2)

Frozen Section Group

EXPERIMENTAL

Participants undergo sentinel lymph node biopsy with intraoperative frozen section examination. Sentinel lymph nodes are identified using blue dye and a gamma probe, and intraoperative decision-making regarding additional axillary intervention is based on frozen section results.

Diagnostic Test: Intraoperative Frozen Section Examination of Sentinel Lymph Node

Routine Histopathology Group

ACTIVE COMPARATOR

Participants undergo sentinel lymph node biopsy without intraoperative frozen section. Sentinel lymph nodes are identified using blue dye and a gamma probe, then processed after formaldehyde fixation with routine histopathological evaluation. Further axillary treatment is decided according to final pathology and tumor board assessment.

Diagnostic Test: Routine Postoperative Histopathological Evaluation of Sentinel Lymph Node

Interventions

Sentinel lymph nodes are rapidly transported to pathology without formaldehyde fixation and are evaluated intraoperatively by frozen section.

Frozen Section Group

Sentinel lymph nodes are processed after formaldehyde fixation and evaluated with routine histopathology after surgery.

Routine Histopathology Group

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with breast carcinoma
  • No prior neoadjuvant treatment

You may not qualify if:

  • Inability to localize the sentinel lymph node preoperatively by lymphoscintigraphy or blue dye
  • Previous axillary surgery
  • Recurrent breast cancer
  • Patients who cannot receive radiotherapy
  • Prior neoadjuvant treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

SBÜ İzmir Şehir Hastanesi

Izmir, İzmir, 35100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Orhan Ureyen, Prof. / MD

    Izmir City Hospital / General Surgery

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
No masking is applied. Surgeons and pathologists are aware of the intraoperative frozen section assessment.
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 3, 2026

First Posted

May 15, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 1, 2027

Last Updated

May 15, 2026

Record last verified: 2026-05

Locations